ResearcherSun Yat-sen UniversityNo recent work listed
Hong Su
Matched on ORCID iD 0009-0001-7780-9268; OpenAlex author ID A5108811679. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2018: 1 paper · 2019: 1 paper · 2020: 2 papers
Papers 4
- Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.lfs.2020.118302↗
- Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and Anticipation of Human Efficacious Doses. Co-author DOI 10.1016/j.xphs.2019.10.035↗
- N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1DR activation. Co-author DOI 10.1016/j.taap.2019.114789↗
- MMP1/PAR1/SP/NK1R paracrine loop modulates early perineural invasion of pancreatic cancer cells. Co-author DOI 10.7150/thno.24281↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ye Yao · 3 shared papers, 2019–2020 · strength 0.30
- Paper Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and… DOI 10.1016/j.xphs.2019.10.035↗
- Paper Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocar… DOI 10.1016/j.lfs.2020.118302↗
- Paper N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1… DOI 10.1016/j.taap.2019.114789↗
- Chunyi Hao · 3 shared papers, 2019–2020 · strength 0.30
- Paper Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and… DOI 10.1016/j.xphs.2019.10.035↗
- Paper Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocar… DOI 10.1016/j.lfs.2020.118302↗
- Paper N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1… DOI 10.1016/j.taap.2019.114789↗
- Tianyan Zhou · 3 shared papers, 2019–2020 · strength 0.30
- Paper Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and… DOI 10.1016/j.xphs.2019.10.035↗
- Paper Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocar… DOI 10.1016/j.lfs.2020.118302↗
- Paper N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1… DOI 10.1016/j.taap.2019.114789↗
- Qingyu Yao · 3 shared papers, 2019–2020 · strength 0.30
- Paper Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and… DOI 10.1016/j.xphs.2019.10.035↗
- Paper Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocar… DOI 10.1016/j.lfs.2020.118302↗
- Paper N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1… DOI 10.1016/j.taap.2019.114789↗
- Junsheng Xue · 2 shared papers, 2019–2020 · strength 0.19
- Paper Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocar… DOI 10.1016/j.lfs.2020.118302↗
- Paper N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1… DOI 10.1016/j.taap.2019.114789↗
- Can Cui · 1 shared paper, 2020 · strength 0.11
- Chumei Huang · 1 shared paper, 2018 · strength 0.07
- Yinting Chen · 1 shared paper, 2018 · strength 0.07
- Jiajia Li · 1 shared paper, 2018 · strength 0.07
- Guoda Lian · 1 shared paper, 2018 · strength 0.07
- Shaojie Chen · 1 shared paper, 2018 · strength 0.07
- Jian Li · 1 shared paper, 2018 · strength 0.07
- Linjuan Zeng · 1 shared paper, 2018 · strength 0.07
- Yaqing Li · 1 shared paper, 2018 · strength 0.07
- Kege Yang · 1 shared paper, 2018 · strength 0.07
- Kaihong Huang · 1 shared paper, 2018 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.